摘要
控制免疫系统主动攻击肿瘤组织的能力将会是一种与癌症持续攻击博斗的非凡武器。不幸的是,癌症治疗还没有可以获得这种控制力的安全有效方法。为了克服这种控制的障碍,白介素12 (IL-12)肿瘤靶向质粒DNA可以被安全投递到常见肿瘤,并且这些治疗可以诱导处理后和未经处理的肿瘤的抗癌免疫应答。在此,电穿孔介导的ttIL-12pDNA在犬自然发生肿瘤的剂量递增研究中表现出安全且耐受性良好。在剂量递增研究中存活的犬给予3800 μg pDNA,分配于 5种独立的犬磷状细胞癌,相当于I期临床试验服用的野生型IL-12 pDNA剂量。任何一个病人在5种不同剂量水平下未发生严重不良事件,并且参数测试只记录了轻微短暂的变化。在治疗与未治疗的病灶中的临床反应分析和mRNA免疫标志物检测暗示:ttIL-12 pDNA 治疗在少数肿瘤中可以引起病灶治疗及远处转移病灶的抗肿瘤免疫应答。这些观察结果表明ttIL-12 pDNA临床剂量可以被安全服用,并且 这些治疗会影响处理过和未处理的转移灶。
关键词: 癌症,犬,电穿孔,基因治疗,免洗疗法,白细胞介素12,肿瘤靶向
Current Gene Therapy
Title:Safety and Efficacy of Tumor-Targeted Interleukin 12 Gene Therapy in Treated and Non-Treated, Metastatic Lesions
Volume: 15 Issue: 1
Author(s): Jeffry Cutrera, Glenn King, Pamela Jones, Kristin Kicenuik, Elias Gumpel, Xueqing Xia and Shulin Li
Affiliation:
关键词: 癌症,犬,电穿孔,基因治疗,免洗疗法,白细胞介素12,肿瘤靶向
摘要: The ability to control the immune system to actively attack tumor tissues will be a marvelous weapon to combat the persistent attack of cancer. Unfortunately, safe and effective methods to gain this control are not yet available as cancer therapies. To overcome the impediments to this control, tumor-targeted (tt) Interleukin 12 (IL-12) plasmid DNA can be safely delivered to accessible tumors, and these treatments can induce antitumor immune responses in both the treated and untreated tumors. Here, electroporationmediated ttIL-12 pDNA treatments are shown to be safe and well tolerated in a dose escalation study in canines bearing naturally-occurring neoplasms. The final patient in the dose-escalation study received up to 3,800 μg pDNA distributed among five separate squamous cell carcinoma tumors in doses equivalent to those administered in a Phase I trial with wildtype IL-12 pDNA. Not a single severe adverse event occurred in any patient at any of the five dose levels, and only minor, transient changes were noted in any tested parameter. Clinical response analysis and immune marker mRNA detection of treated and non-treated lesions suggest that ttIL-12 pDNA treatments in only a few tumors can elicit antitumor immune responses in the treated lesions as well as distant metastatic lesions. These observations and results demonstrate that ttIL-12 pDNA can be safely administered at clinical levels, and these treatments can affect both treated and nontreated, metastatic lesions.
Export Options
About this article
Cite this article as:
Jeffry Cutrera, Glenn King, Pamela Jones, Kristin Kicenuik, Elias Gumpel, Xueqing Xia and Shulin Li , Safety and Efficacy of Tumor-Targeted Interleukin 12 Gene Therapy in Treated and Non-Treated, Metastatic Lesions, Current Gene Therapy 2015; 15 (1) . https://dx.doi.org/10.2174/1566523214666141127093654
DOI https://dx.doi.org/10.2174/1566523214666141127093654 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Melatonin Signaling in Health and Disease
Melatonin regulates a multitude of physiological functions, including circadian rhythms, acting as a scavenger of free radicals, an anti-inflammatory agent, a modulator of mitochondrial homeostasis, an antioxidant, and an enhancer of nitric oxide bioavailability. AANAT is the rate-limiting enzyme responsible for converting serotonin to NAS, which is further converted to ...read more
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers.
Programmed cell death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
The now and future of gene transfer technologies
Gene and cell therapies rely on a gene delivery system which is safe and effective. Both viral and non-viral vector systems are available with specific pros and cons. The choice of a vector system is largely dependent on the application which is a balance between target tissue/disease and safety, efficacy ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion
Mini-Reviews in Medicinal Chemistry Ferulic Acid Activity in Topical Formulations: Technological and Scientific Prospecting
Current Pharmaceutical Design HPV and Therapeutic Vaccines: Where are We in 2010?
Current Cancer Therapy Reviews Editorial (Hot Topic: miRNA in the Pathogenesis and Therapy for Gastrointestinal and Hepatic Cancers)
Current Pharmaceutical Design New Target Therapies for Brain Metastases from Breast Cancer
Current Cancer Drug Targets Proteomic Identification of a Monoclonal Antibody Recognizing Caveolin-1 in Hepatocellular Carcinoma with Metastatic Potential
Protein & Peptide Letters Statins-Mediated Inhibition of Rho GTPases as a Potential Tool in Anti-Tumor Therapy
Mini-Reviews in Medicinal Chemistry Potential Beneficial Effects of Garlic in Oncohematology
Mini-Reviews in Medicinal Chemistry Molecular Imaging of Apoptosis with Radio-Labeled Annexin A5 Focused on the Evaluation of Tumor Response to Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Direct Targeting of the Ras GTPase Superfamily Through Structure- Based Design
Current Topics in Medicinal Chemistry Toxicity, Genotoxicity, and Carcinogenicity of Isotretinoin
Current Molecular Pharmacology Targeted Ultrasound Imaging of Cancer: An Emerging Technology on its Way to Clinics
Current Pharmaceutical Design Novel Strategies for Effective Actinic Keratosis Treatment: A Review
Current Cancer Therapy Reviews Cancer Prevention with Promising Natural Products: Mechanisms of Action and Molecular Targets
Anti-Cancer Agents in Medicinal Chemistry “Smart” Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems
Drug Delivery Letters Pharmacological Inhibition of the Bcl-2 Family of Apoptosis Regulators as Cancer Therapy
Current Molecular Pharmacology Ceramidases in Hematological Malignancies: Senseless or Neglected Target?
Anti-Cancer Agents in Medicinal Chemistry Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters HGF and RhoGTPases in Cancer Cell Motility
Current Signal Transduction Therapy Molecular Modeling Applied to Anti-Cancer Drug Development
Anti-Cancer Agents in Medicinal Chemistry